Skip to main content

Summary

at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

To allow continuation of treatment of patients experiencing benefit from AG 013736

Official Title

Continuing Access To The Tyrosine Kinase Inhibitor Of Vegfr 2, Ag 013736 (a406) For Patients Previously Receiving Ag 013736 In Clinical Trials

Keywords

Solid Tumors VEGFR inhibitor angi-angiogenic tyrosine kinase inhibitor Axitinib

Eligibility

You can join if…

  • Patients who were assigned to an axitinib containing treatment arm in a previous clinical trial
  • Patients who were receiving axitinib tablets at the time their previous trial ended
  • Patients who have stable (SD) or responding disease (PR or CR) documented by the appropriate radiological, clinical, or laboratory assessments within 12 weeks before enrollment (Note: response criteria from the previous AG-013736 protocol should be used to determine stable or responding disease).
  • Patients who have progressive disease (PD) but have experienced "clinical benefit" as defined in the study protocol

You CAN'T join if...

  • Patients may not participate in this trial if the conditions for continuing treatment in the previous AG-013736 protocol are not met

Locations

  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California, 94158, United States
  • UCLA Hematology-Oncology-Santa Monica
    Santa Monica, California, 90404, United States
  • UC Irvine Medical Center
    Orange, California, 92868, United States
  • University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center
    Orange, California, 92868, United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
Links
To obtain contact information for a study center near you, click here.
ID
NCT00828919
Lead Scientist
Charles Ryan
Study Type
Interventional
Last Updated
September 28, 2017